SIO 2025 Oncology Acupuncture 101 Workshop Highlights a Decade of Progress and Global Collaboration
Boston, MA—October 27, 2025
The Society for Integrative Oncology (SIO) 2025 pre-conference workshop, Oncology Acupuncture 101: Guideline-Based Foundations & Safety Strategies, took place at Harvard Medical School’s Joseph B. Martin Conference Center, bringing together over 93 participants from nine countries.
Led by Dr. Weidong Lu of Dana-Farber Cancer Institute/Harvard Medical School, the workshop marked ten years since the inaugural SIO Oncology Acupuncture training in 2015. Faculty from leading institutions including the National Cancer Institute (Dr. Libin Jia), NYU Perlmutter Cancer Center (Dr. Iris Zhi), Fred Hutchinson Cancer Center (Dr. Susan Veleber), and Tel Aviv Integrative Oncology Center (Dr. Yair Maimon)
joined Dana-Farber’s acupuncture team to deliver evidence-based and practical education.
The workshop emphasized safety and clinical precision through the Red/Amber/Green safety triage algorithm, guideline-directed indications, and two validated treatment protocols:
- Chemotherapy-induced nausea and vomiting (CINV) – Electroacupuncture protocol
- Aromatase-inhibitor-related joint pain (AI arthralgia) – Manual acupuncture protocol
Dr. Lu stated, “This workshop shows how far oncology acupuncture has evolved — from a single-center effort to a globally shared clinical discipline. The next decade will focus on standardized training, safety, and access for patients who need it most.”
Dana-Farber plans to build on this momentum by launching Oncology Acupuncture 102 (Advanced Training), pursuing NIH R25/T32 education grants, and expanding international collaboration and open-access dissemination via Zenodo and SIO platforms.
國際整合腫瘤學會（SIO）腫瘤針灸訓練研討會
十年發展再創里程碑
美國波士頓—2025年10月27日
2025年國際整合腫瘤學會（SIO）年會前舉行的專題研討會《腫瘤針灸101：循證基礎與安全策略》在哈佛醫學院Joseph B. Martin會議中心成功舉辦，吸引了來自9個國家的93位專業人士參加。
本次研討會由達納法伯癌症研究院/哈佛醫學院陸衛東博士主持，標誌著自2015年首屆SIO腫瘤針灸培訓以來的十週年。來自美國國家癌症研究所賈力斌博士、紐約大學Iris Zhi博士、弗雷德哈金森癌症中心Susan Veleber博士、以色列Yair Maimon博士等國際知名專家與達納法伯針灸團隊共同授課。
課程重點介紹了紅/黃/綠安全分級演算法、國際指南推薦的針灸適應症，並提供了兩個經過驗證的臨床方案：
- 化療相關噁心嘔吐（CINV）—電針方案
- 芳香化酶抑制剂相關關節疼痛（AI關節痛）一手針方案
陸博士指出：“十年來，腫瘤針灸已從單一中心的探索走向全球協作的臨床專科。下一階段的重點是建立標準化培訓體系，保障安全與療效，讓更多癌症患者受益。”
達納法伯癌症研究院計劃繼續推動腫瘤針灸102高級課程、申請NIH R25/T32教育計畫資助，並透過Zenodo與SIO平台開展全球開放獲取與合作，持續引領腫瘤針灸教育與研究發展。
